Glipizide and Cozaar drug interactions - from FDA reports

Summary

Drug interactions are reported among people who take Glipizide and Cozaar together. This study is created by eHealthMe based on reports of 792 people who take Glipizide and Cozaar from FDA, and is updated regularly.



What's eHealthMe?

eHealthMe is a health data analysis company based in Mountain View, California. eHealthMe monitors and analyzes the outcomes of drugs and supplements that are currently on the market. The results are readily available to health care professionals and consumers.

eHealthMe has released original studies on market drugs and worked with leading universities and institutions such as IBM, London Health Science Centre, Mayo Clinic, Northwestern University and VA. eHealthMe studies have now been referenced in over 500 peer-reviewed medical publications.

How we gather our data?

Healthcare data is obtained from a number of sources including the Food and Drug Administration (FDA). This information is aggregated and used to produce personalized reports that patients can reference.

The information that eHealthMe collects includes:

  • Side effects (including severity and how people recover from them)
  • Associated conditions or symptoms
  • Drug effectiveness
  • Demographic data regarding drug use

How the study uses the data?

The study is based on glipizide and losartan potassium (the active ingredients of Glipizide and Cozaar, respectively), and Glipizide and Cozaar (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered.

What is Glipizide?

Glipizide has active ingredients of glipizide. It is often used in diabetes. (latest outcomes from Glipizide 44,241 users)

What is Cozaar?

Cozaar has active ingredients of losartan potassium. It is often used in high blood pressure. (latest outcomes from Cozaar 37,171 users)

How to use the study?

Patients can bring a copy of the report to their healthcare provider to ensure that all drug risks and benefits are fully discussed and understood. It is recommended that patients use the information presented as a part of a broader decision-making process.


On Mar, 14, 2019

792 people who take Glipizide, Cozaar are studied.


Number of reports submitted per year:

Glipizide and Cozaar drug interactions.

Most common drug interactions over time *:

< 1 month:
  1. Back pain
  2. Paraesthesia oral (sensation of tingling, tickling, prickling, pricking, or burning of a person's oral with no apparent long-term physical effect)
  3. Alopecia (absence of hair from areas of the body)
  4. Blood glucose increased
  5. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
  6. Cough
  7. Dizziness
  8. Dysphagia (condition in which swallowing is difficult or painful)
  9. Gait disturbance
  10. Influenza
1 - 6 months:
  1. Hypoxia (low oxygen in tissues)
  2. Anxiety
  3. Emotional distress
  4. Fear
  5. Injury
  6. Pain
  7. Renal failure (kidney dysfunction)
  8. Renal impairment (severely reduced kidney function)
  9. Renal injury (kidney injury)
  10. Renal transplant
6 - 12 months:
  1. Chronic kidney disease
  2. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  3. Weight decreased
1 - 2 years:
  1. Cardiac arrest
  2. Coma (state of unconsciousness lasting more than six hours)
  3. Constipation
  4. Hypovolaemic shock (shock caused by severe blood or fluid loss)
  5. Metabolic acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body)
  6. Angioedema (rapid swelling of the dermis)
  7. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  8. Anorexia (eating disorder characterized by immoderate food restriction and irrational fear of gaining weight)
  9. Anxiety
  10. Asthenia (weakness)
2 - 5 years:
  1. Alopecia (absence of hair from areas of the body)
  2. Back pain
  3. Blood glucose increased
  4. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
  5. Cough
  6. Dizziness
  7. Dysphagia (condition in which swallowing is difficult or painful)
  8. Gait disturbance
  9. Influenza
  10. Lip dry
5 - 10 years:
  1. Epistaxis (bleed from the nose)
  2. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  3. Haemorrhagic stroke (stroke caused by the rupture of a blood vessel in the brain)
  4. Death
10+ years:
  1. Alopecia (absence of hair from areas of the body)
  2. Blood glucose increased
  3. Nephrolithiasis (calculi in the kidneys)
  4. Paraesthesia oral (sensation of tingling, tickling, prickling, pricking, or burning of a person's oral with no apparent long-term physical effect)
  5. Pruritus (severe itching of the skin)
  6. Rhinorrhoea (watery mucus discharge from the nose)
  7. Sneezing
  8. Back pain
  9. Dysphagia (condition in which swallowing is difficult or painful)
  10. Gait disturbance
not specified:
  1. Nausea (feeling of having an urge to vomit)
  2. Pain
  3. Fatigue (feeling of tiredness)
  4. Anxiety
  5. Asthenia (weakness)
  6. Blood glucose increased
  7. Dyspnoea (difficult or laboured respiration)
  8. Anaemia (lack of blood)
  9. Weight decreased
  10. Cardiac failure congestive

Most common drug interactions by gender *:

female:
  1. Gait disturbance
  2. Muscle spasms (muscle contraction)
  3. Cough
  4. Myalgia (muscle pain)
  5. Pain in extremity
  6. Dysphagia (condition in which swallowing is difficult or painful)
  7. Fatigue (feeling of tiredness)
  8. Blood glucose decreased
  9. Dyspnoea (difficult or laboured respiration)
  10. Dizziness
male:
  1. Fatigue (feeling of tiredness)
  2. Anaemia (lack of blood)
  3. Renal failure acute (rapid kidney dysfunction)
  4. Diarrhoea
  5. Hypotension (abnormally low blood pressure)
  6. Vomiting
  7. Coronary artery disease (plaque building up along the inner walls of the arteries of the heart, which narrows the arteries and restricts blood flow to the heart)
  8. Injury
  9. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  10. Arthralgia (joint pain)

Most common drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:
  1. Fatigue (feeling of tiredness)
  2. Myalgia (muscle pain)
  3. Asthenia (weakness)
  4. Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
  5. Urinary tract infection
  6. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  7. Anxiety
  8. Bone callus excessive (excessive bony deposit formed between and around the broken ends of bone fractures)
  9. Bruxism (habitual grinding of the teeth, typically during sleep)
  10. Cardiovascular disorder (heart diseases)
40-49:
  1. Nausea (feeling of having an urge to vomit)
  2. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)
  3. Asthma
  4. Coronary artery disease (plaque building up along the inner walls of the arteries of the heart, which narrows the arteries and restricts blood flow to the heart)
  5. Weight decreased
  6. Vomiting
  7. Blood glucose increased
  8. Fluid retention (an abnormal accumulation of fluid in the blood)
  9. Headache (pain in head)
  10. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
50-59:
  1. Weight decreased
  2. Drug ineffective
  3. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  4. Congestive cardiomyopathy (weakening of heart muscle)
  5. Fatigue (feeling of tiredness)
  6. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
  7. Coronary artery disease (plaque building up along the inner walls of the arteries of the heart, which narrows the arteries and restricts blood flow to the heart)
  8. Flushing (the warm, red condition of human skin)
  9. Pancreatitis acute (sudden inflammation of pancreas)
  10. Dyspnoea (difficult or laboured respiration)
60+:
  1. Dyspnoea (difficult or laboured respiration)
  2. Nausea (feeling of having an urge to vomit)
  3. Cardiac failure congestive
  4. Cough
  5. Diarrhoea
  6. Pain
  7. Back pain
  8. Renal failure acute (rapid kidney dysfunction)
  9. Malaise (a feeling of general discomfort or uneasiness)
  10. Myocardial infarction (destruction of heart tissue resulting from obstruction of the blood supply to the heart muscle)

* Approximation only. Some reports may have incomplete information.

Do you take Glipizide and Cozaar?


You are not alone:




Related publications that referenced our studies


Results from eHealthMe (non-FDA) reports of taking Glipizide and Cozaar together

Drug effectiveness (drug is found to be effective) over time *:
Glipizide:
  • < 1 month: 0.0% (0 of 0 people)
  • 1 - 6 months: 0.0% (0 of 0 people)
  • 6 - 12 months: 0.0% (0 of 1 people)
  • 1 - 2 years: 100% (1 of 1 people)
  • 2 - 5 years: 0.0% (0 of 2 people)
  • 5 - 10 years: 0.0% (0 of 0 people)
  • 10+ years: 0.0% (0 of 0 people)
  • not specified: 100% (1 of 1 people)
Cozaar:
  • < 1 month: 0.0% (0 of 0 people)
  • 1 - 6 months: 0.0% (0 of 1 people)
  • 6 - 12 months: 0.0% (0 of 0 people)
  • 1 - 2 years: 100% (1 of 1 people)
  • 2 - 5 years: 0.0% (0 of 0 people)
  • 5 - 10 years: 50% (1 of 2 people)
  • 10+ years: 100% (2 of 2 people)
  • not specified: 0.0% (0 of 0 people)
Drug effectiveness (drug is found to be effective) by gender *:
Glipizide:
  • female: 33% (1 of 3 people)
  • male: 50% (1 of 2 people)
Cozaar:
  • female: 100% (3 of 3 people)
  • male: 33% (1 of 3 people)
Drug effectiveness (drug is found to be effective) by age *:
Glipizide:
  • 0-1: 0.0% (0 of 0 people)
  • 2-9: 0.0% (0 of 0 people)
  • 10-19: 0.0% (0 of 0 people)
  • 20-29: 0.0% (0 of 0 people)
  • 30-39: 0.0% (0 of 0 people)
  • 40-49: 0.0% (0 of 0 people)
  • 50-59: 0.0% (0 of 2 people)
  • 60+: 66.0% (2 of 3 people)
Cozaar:
  • 0-1: 0.0% (0 of 0 people)
  • 2-9: 0.0% (0 of 0 people)
  • 10-19: 0.0% (0 of 0 people)
  • 20-29: 0.0% (0 of 0 people)
  • 30-39: 0.0% (0 of 0 people)
  • 40-49: 0.0% (0 of 0 people)
  • 50-59: 100.0% (2 of 2 people)
  • 60+: 50.0% (2 of 4 people)
Race of the people *:
  • African American, Non-Hispanic: 7.14 %
  • American Indian/Alaska Native: 0.0 %
  • Asian: 0.0 %
  • Hispanic: 0.0 %
  • Native Hawaiians/Pacific Islanders: 0.0 %
  • Two or more races: 0.0 %
  • White, Non-Hispanic: 92.86 %

* Approximation only.


Related studies

Browse interactions by gender and age

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+


Interactions between Glipizide and drugs from A to Z
a b c d e f g h i j k l m n o p q r s t u v w x y z
Interactions between Cozaar and drugs from A to Z
a b c d e f g h i j k l m n o p q r s t u v w x y z
Browse all drug interactions of Glipizide and Cozaar
a b c d e f g h i j k l m n o p q r s t u v w x y z

What would happen?

Predict new side effects and undetected conditions when you take Glipizide and Cozaar



FDA reports used in this study


Recent updates

Recent general studies
Recent personal studies


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Submit your testimonial

  • Please fill in your Testimonial.
  • Please enter a minimum of 10 characters for your Testimonial.
  • Please fill in your Name.

Please wait...

{progressItem}

Thank you!